Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regeneron Pharmaceuticals' Eylea (aflibercept) injection, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD), has earned FDA approval.
Subscribe to our email newsletter
Eylea is a recombinant fusion protein, that binds VEGF-A and placental growth factor (PlGF) to inhibit the binding and activation of these cognate VEGF receptors.
The recommended dose for Eylea injection is 2 mg administered by intravitreal injection every four weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every eight weeks (2 months).
Two Phase 3 clinical studies – View 1 and View 2, which proved the efficacy of Eylea in being clinically equivalent to the ranibizumab, led to the approval.